Great breakdown from McKinsey & Company here on current Medicare Advantage dynamics. TL;DR they have some levers but margins are as thin as they've been in recent memory in 2024. McKinsey called out the following as challenges for MA players moving forward: -Little to no rate increases from CMS -Broker commissions changes -V28 changes -Star ratings (the biggest near-term lever) -Utilization trends -Part D and other regulatory changes Source: https://lnkd.in/g9U4h2Gp
Let's talk about the major flaw in the article. The pickleball players are standing in the wrong locations!
How about abandoning subscribers in "unprofitable" markets, and tuning up the denials and downcoding. . .
I can solve this very quickly. Decrease the admin costs by removing prior auth and have broker commissions cut in half. Shouldn’t need to sell an insurance plan that makes it harder to access care. These plans have co-pays/co insurance as well which should adjust cost enough. I fixed it. But would love to hear the other side.
Thanks Blake for sharing. Agree with your synopsis. We’ll see how much comes out of benefits shortly…
Managing Director at Kaufman Strategic Advisors
6moHow about more aggressive risk scoring, increasing denials, delays, and down coding, increasing retail drug costs to increase revenues outside of the MLR formula, and capturing more rebates in offshore rebate aggregators?